公开(公告)号：US20040265320A1

公开(公告)日：2004-12-30

申请号：US10766528

申请日：2004-01-29

Inventor： Karl Salzwedel ,  Feng Li ,  Carl T. Wild ,  Graham P. Allaway ,  Eric O. Freed

IPC: A61K039/42

CPC classification number: A61K45/06 ,  A61K31/56 ,  C07K14/005 ,  C12N2740/16043 ,  C12N2740/16222 ,  G01N2333/161 ,  A61K2300/00

Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

Abstract translation: 公开了通过破坏来自CA-间隔肽1（SP1）蛋白前体（p25）的病毒Gag衣壳（CA）蛋白（p24））的加工来抑制HIV-1复制。 含有Gag p25蛋白突变的氨基酸序列，突变导致二甲基琥珀酰桦树酸或二甲基琥珀酰基桦木醇处理p25至p24的抑制作用降低，编码这种突变序列的多核苷酸和选择性结合这种突变序列的抗体是 也包括在内。 包括抑制，抑制化合物的方法和发现靶向HIV Gag蛋白的蛋白水解加工的抑制性化合物的方法。 在一个实施方案中，这样的化合物通过结合Gag蛋白水解切割位点而不是蛋白酶抑制HIV蛋白酶与Gag的相互作用。 在另一个实施方案中，在Gag蛋白水解切割位点区域中含有突变的病毒或重组蛋白质可用于筛选测定以鉴定靶向蛋白水解加工的化合物。

公开(公告)号：US20040258664A1

公开(公告)日：2004-12-23

申请号：US10488402

申请日：2004-03-03

Inventor： Jacob Pitcovski ,  Ely Morag ,  Yosef Pinchasov

IPC: A61K048/00 ,  A61K039/40 ,  A61K039/42

CPC classification number: C07K16/1275 ,  A61K2039/505 ,  C07K16/1203 ,  C07K16/1232 ,  C07K2317/11 ,  C07K2317/77

Abstract: AbstractThe present invention relates to a multi-functional targeting complex for inducing a specific immuno-stimulatory reaction, preferably, phagocytosis, against at least one target pathogenic agent. The complex of the invention comprises at least one target recognition component comprising a molecule that specifically binds to the desired target agent, an immuno-active component comprising an immuno-stimulatory agent; and optionally, a connecting component that associates the targeting component and the immuno-active component. The complex of the invention provides an effective therapeutic prevention and treatment of various pathogenic disorders, such as mastitis in caws and furunculosis in fish. The invention further relates to compositions comprising the targeting complex, methods of treatment and uses thereof.

Abstract translation: 摘要本发明涉及一种多功能靶向复合物，其用于针对至少一种靶病原体诱导特异性免疫刺激反应，优选为吞噬作用。 本发明的复合物包含至少一种目标识别组分，其包含特异性结合所需目标试剂的分子，包含免疫刺激剂的免疫活性组分; 以及任选地，将靶向组分和免疫活性组分相关联的连接组分。 本发明的复合物提供了有效的治疗性预防和治疗各种致病性疾病，例如鱼中的乳腺炎和鱼中的fur疮。 本发明还涉及包含靶向复合物，治疗方法及其应用的组合物。

公开(公告)号：US20040214994A1

公开(公告)日：2004-10-28

申请号：US10480843

申请日：2004-02-23

Inventor： Roberto Burioni ,  Massimo Clementi

IPC: C07H021/04 ,  A61K039/42 ,  A61K048/00

CPC classification number: C07K16/109 ,  A61K48/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C12N2799/028

Abstract: An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof.

Abstract translation: 描述了丙型肝炎病毒（HCV）的人抗体抗NS3蛋白，以及能够在体外和体内抑制NS3蛋白的解旋酶活性的合成和重组片段及其用途。

公开(公告)号：US20040197338A1

公开(公告)日：2004-10-07

申请号：US10480965

申请日：2004-05-24

Inventor： Robert Paul Yeo

IPC: A61K039/42 ,  C07K016/10

CPC classification number: C07K16/1027 ,  C07K2317/34

Abstract: Respiratory syncytial virus, or RSV, is a cause of respiratory tract infection in humans and other animals. Replication of the virus relies in part upon the association of the nucleocapsid (N) protein with a phosphoprotein (P protein). The present invention describes the identification and sequencing of peptide fragments which bind to the P protein and which disrupt the interaction of the N and P proteins. Such peptides may be used to inhibit replication of RSV, and for treatment of patients infected with RSV. Further aspects of the invention relate to the use of such peptides in the diagnosis of RSV infection.

Abstract translation: 呼吸道合胞病毒或RSV是人类和其他动物呼吸道感染的原因。 病毒的复制部分依赖于核衣壳（N）蛋白与磷蛋白（P蛋白）的结合。 本发明描述了与P蛋白结合并破坏N和P蛋白相互作用的肽片段的鉴定和测序。 这样的肽可以用于抑制RSV的复制，以及用于治疗感染RSV的患者。 本发明的其它方面涉及这样的肽在诊断RSV感染中的用途。

公开(公告)号：US20040181041A1

公开(公告)日：2004-09-16

申请号：US10478741

申请日：2004-05-11

Inventor： David B. Weiner

IPC: A61K039/42 ,  C07K016/46

CPC classification number: C07K14/4747 ,  C07K2319/00

Abstract: Fusion proteins which comprise an apoptosis inducing protein portion and a cell targeting portion are disclosed. Fusion proteins which comprise a protease portion and a cell targeting portion are disclosed. Compositions for and methods of targeting and inducing the death of cells are disclosed.

Abstract translation: 公开了包含凋亡诱导蛋白质部分和细胞靶向部分的融合蛋白。 公开了包含蛋白酶部分和细胞靶向部分的融合蛋白。 公开了靶向和诱导细胞死亡的组合物和方法。

公开(公告)号：US20040131622A1

公开(公告)日：2004-07-08

申请号：US10642122

申请日：2003-08-15

Applicant: Board of Regents ,  The University of Texas System

Inventor： Philip E. Thorpe ,  M. Melina Soares ,  Sophia Ran

IPC: A61K039/42

CPC classification number: A61K39/395 ,  A61K39/39558 ,  A61K47/62 ,  A61K47/6811 ,  A61K47/6835 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/2836 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  A61K2300/00

Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

Abstract translation: 公开了关于阴离子磷脂和氨基磷脂在肿瘤脉管系统和病毒进入和扩散中的作用的令人惊奇的发现，以及将这些发现用于治疗癌症和病毒感染的组合物和方法。 还公开了结合和抑制阴离子磷脂和氨基磷脂的有利的抗体，免疫缀合物和基于杜氏霉素的组合物和组合，用于安全和有效治疗癌症，病毒感染和相关疾病。

公开(公告)号：US20040091487A1

公开(公告)日：2004-05-13

申请号：US10624080

申请日：2003-07-21

Inventor： Ganjam V. Kalpana

IPC: A61K039/42

CPC classification number: C07K14/4703 ,  G01N2333/16 ,  G01N2500/10

Abstract: Peptides comprising an Rpt1 domain of an INI1/hSNF5 which inhibit HIV-1 production in a human cell, and vectors encoding those peptides are provided. Also provided are methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by treating the cells with the above peptides or vectors. Other methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by inhibiting production of INI1/hSNF5 are provided. Additionally, methods of determining whether a test compound inhibits HIV-1 virion production in a mammalian cell, or spread of the HIV-1 to another cell, are provided. Those methods comprise determining whether the test compound inhibits the production of INI1/hSNF5 or disrupts the interaction of HIV-1 integrase with INI1/hSNF5.

Abstract translation: 提供了包含抑制人细胞中HIV-1产生的INI1 / hSNF5的Rpt1结构域的肽和编码这些肽的载体。 还提供了通过用上述肽或载体处理细胞来抑制细胞中HIV-1产生或HIV-1扩散到另一细胞的方法。 提供了通过抑制INI1 / hSNF5的产生来抑制细胞中HIV-1产生或HIV-1向另一细胞扩散的其它方法。 此外，提供了确定测试化合物是否抑制哺乳动物细胞中的HIV-1病毒粒子产生或HIV-1向另一个细胞扩散的方法。 这些方法包括确定测试化合物是否抑制INI1 / hSNF5的产生或破坏HIV-1整合酶与INI1 / hSNF5的相互作用。

公开(公告)号：US20040009177A1

公开(公告)日：2004-01-15

申请号：US10420387

申请日：2003-04-18

Inventor： Ralph A. Tripp ,  Les Jones ,  Larry J. Anderson

IPC: A61K038/10 ,  A61K039/42

CPC classification number: C07K9/00 ,  A61K38/00 ,  A61K39/00 ,  C07K14/005 ,  C07K16/1027 ,  C12N2760/18522

Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.

Abstract translation: 提供了通过调节RSV感染和免疫来治疗或预防RSV疾病的组合物和方法。 特别地，鉴定出含有定义为C-X-X-X-C（或CX3C）的趋化因子基序的RSV G糖蛋白中的氨基酸序列，其是引起RSV感染和疾病所必需的。 趋化因子基序具有生物活性，并参与病毒与敏感细胞的结合和感染。 RSV感染的预防或治疗通过干扰基序来实现，例如通过施用其中基序被改变的疫苗或通过施用或诱导抑制基序生物活性的阻断分子来实现。

公开(公告)号：US20030232045A1

公开(公告)日：2003-12-18

申请号：US10367418

申请日：2003-02-14

Inventor： Elliot R. Ramberg ,  Martin J. Lopez

IPC: A61K039/395 ,  A61K039/42 ,  A61K039/40

CPC classification number: A61K35/18 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/31 ,  C07K2317/50 ,  Y02A50/403

Abstract: The present invention provides methods and compositions using biological factors, such as complement components, and manipulation of cells of erythroblastic lineage and myeloid lineage to facilitate clearance of pathologic targets from the blood stream of a patient in specific phagocytic compartment.

Abstract translation: 本发明提供使用诸如补体成分的生物因子和操作红细胞谱系和骨髓谱系细胞的方法和组合物，以便于从特定吞噬室中的患者血流清除病理学靶标。

公开(公告)号：US20030211470A1

公开(公告)日：2003-11-13

申请号：US10386763

申请日：2003-03-12

Inventor： William C. Olson ,  Robert J. Israel

IPC: A61K039/42 ,  C12Q001/70

CPC classification number: C07K16/1045 ,  A61K2039/505 ,  C07K16/06 ,  C07K2317/34 ,  C07K2319/00 ,  C12Q1/703 ,  C12Q2563/113

Abstract: This invention provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193) and the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194). Finally, this invention provides a method of inhibiting HIV infection of a CD4null cell, a method of preventing a subject from being infected with HIV, and a method of treating a subject infected with HIV so as to block the spread of HIV infection, using the above CD-4-IgG2 chimeric heterotetramers.

Abstract translation: 本发明提供了CD4-IgG2嵌合异源四聚体，其中嵌合异源四聚体的重链由称为CD4-IgG2HC-pRcCMV（ATCC No.75193）的表达载体编码。 本发明还提供了CD4-IgG2嵌合异源四聚体，其中嵌合异源四聚体的轻链由称为CD4-kLC-pRcCMV（ATCC No.75194）的表达载体编码。 本发明还提供了CD4-IgG2嵌合异源四聚体，其中嵌合异源四聚体的重链由称为CD4-IgG2HC-pRcCMV（ATCC No.75193）的表达载体编码，并且嵌合异源四聚体的轻链由表达 载体指定为CD4-kLC-pRcCMV（ATCC No.75194）。 最后，本发明提供一种抑制CD4 +细胞的HIV感染的方法，一种预防受试者感染HIV的方法，以及一种治疗HIV感染者的方法，以阻止HIV感染的传播，使用 以上CD-4-IgG2嵌合异源四聚体。